PBL Awarded Major U.S. Patent on Short RNA
News Apr 21, 2010
Plant Bioscience Limited (PBL) announces that the United States Patent Office has allowed claims in its patent application 10/806,253 for detection of short RNA molecules to identify gene silencing in mammals and mammalian cells.
Silencing is a natural phenomenon that occurs in many different organisms from yeasts to plants to humans. It is a central mechanism for modulation of gene expression.
Interest in the detection and use of short RNA molecules (siRNA and miRNA) has seen a dramatic increase over the past few years. Researchers use detection methods to analyze miRNA expression patterns and monitor siRNA levels following induction of silencing, for example to determine whether gene therapy drugs are having their intended effect on the expression of target genes relevant to diseases, such as cancer.
The award of this patent (7,704,688, issue date 27 April 2010) comes as further recognition by the United States Patent Office (USPTO) of the pioneering contributions of Professor Sir David Baulcombe and Dr Andrew Hamilton to the field of gene silencing in living organisms.
The patent was initially filed in 1999, that is, after Andrew Fire and Craig Mello published on the use of dsRNA to induce silencing in nematodes in1998, but before the publication in 2000 of Thomas Tuschl and colleagues’ studies on short RNA molecules in Drosophila. In 2006, Fire and Mello received the Nobel Prize for their work on RNAi.
The first of PBL’s patents to be granted by the USPTO for the work conducted by David Baulcombe and Andrew Hamilton was US Patent No. 6,753,139, which issued in 2004, for methods of detecting gene silencing in plants. Now, following substantial additional examination before the USPTO, claims directed to detection of silencing in mammals, through the detection of short RNA molecules, have also been allowed.
The patent claims derive from research carried out by Baulcombe and Hamilton at The Sainsbury Laboratory in Norwich, UK and published in Science (“A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants”, (1999), 286, pp. 950-952). This paper describes the authors’ ground-breaking work in identifying short RNA molecules as the agents which both signal the occurrence of and induce gene silencing.
At least in part, that work has resulted in the Lasker Foundation awarding the 2008 Albert Lasker Basic Research Award jointly to Gary Ruvkun and Victor Ambrose (for their combined effort in identifying the first miRNA in nematodes), and David Baulcombe (whose work demonstrated that short RNA molecules have a broad applicability as markers and inducers of gene silencing in living organisms) “For discoveries that revealed an unanticipated world of tiny RNAs that regulate gene function in plants and animals”. In addition, in 2009, Professor Baulcombe was awarded a knighthood “for services to Plant Science”.
PBL currently has several further pending patent applications, based on further aspects of the work of Baulcombe and Hamilton, which are being examined by the USPTO, including for the use of short RNA molecules to cause gene silencing, for example, as therapeutic agents.
Professor Sir David Baulcombe says “We are delighted that the US Patent Office has confirmed that our contribution to the field of RNA silencing extends well beyond the work we did in plants as a model system. The topic of RNA silencing in mammals has exploded into a significant field of study involving siRNA and microRNA as key factors in genetic and epigenetic regulation.”
“The grant of the patent further underlines the contribution of our Science publication to understanding the mechanism of gene silencing in biology and we are very pleased that this has now been further recognized by the United States Patent Office”, adds Dr Andrew Hamilton.
“We are thrilled that the patent office has recognized the revolutionary findings from the research carried out at The Sainsbury Laboratory by David and Andrew”, Professor Sophien Kamoun, Head of The Sainsbury Laboratory says. “In addition we congratulate PBL and in particular we recognize their diligent effort and special expertise in prosecuting this patent successfully to grant.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.